http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
.trig | .trig.txt | .jelly | .jelly.txt
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A> .
@prefix sub: <http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
<http://purl.obolibrary.org/obo/DOID_3393> biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object <http://purl.obolibrary.org/obo/DOID_3393>;
rdf:predicate biolink:treats;
rdf:subject <https://identifiers.org/drugbank:DB00998>;
rdfs:label "\"Frovatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions ( 5.4 Peripheral vascular disease [s ee Warnings and Precautions ( 5.5 Ischemic bowel disease [s ee Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.1 7.2 Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [s ee Warnings and Precautions ( 5.9 History of coronary artery disease or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of treatment with another 5-HT 1 4 Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) ( 4\"";
biolink:provided_by <https://w3id.org/um/NeuroDKG>;
biolink:relation schema:MedicalContraindication .
<https://identifiers.org/drugbank:DB00998> biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "cdU6ZiV0jP+1Ptbr+tKIJM91MMjvEPZLvMMLNaPjLDUQ32M06+DVV8x/8IrNgyw3Qd3vMLlJwUpOViSwEtQhqiePf0XpMr1wOMOHq2KmIaXkfTz3RAP9rwyLH4noPzpvu+v05dzEJlnA6lf/NxZXgHLDXDOoy9nl/XGrm1vGQ34=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-23T18:38:13.760+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}